摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(2,4-二氯苯氧基)苯甲腈 | 175136-80-8

中文名称
2-(2,4-二氯苯氧基)苯甲腈
中文别名
2-(2,4-二氯苯氧基)苯腈
英文名称
2-(2,4-dichlorophenoxy)benzonitrile
英文别名
——
2-(2,4-二氯苯氧基)苯甲腈化学式
CAS
175136-80-8
化学式
C13H7Cl2NO
mdl
MFCD00052459
分子量
264.111
InChiKey
UTLUAJUFCRYPDL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.4
  • 重原子数:
    17
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    33
  • 氢给体数:
    0
  • 氢受体数:
    2

安全信息

  • 危险品标志:
    Xn
  • 危险类别码:
    R20/21/22,R36/37/38
  • 海关编码:
    2926909090
  • 安全说明:
    S26,S36/37/39

SDS

SDS:de0f590a1cd2b433b58e1b6d2ff31b7d
查看
Name: 2-(2 4-Dichlorophenoxy)benzonitrile 97% Material Safety Data Sheet
Synonym:
CAS: 175136-80-8
Section 1 - Chemical Product MSDS Name:2-(2 4-Dichlorophenoxy)benzonitrile 97% Material Safety Data Sheet
Synonym:

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
CAS# Chemical Name content EINECS#
175136-80-8 2-(2,4-Dichlorophenoxy)benzonitrile 97% unlisted
Hazard Symbols: XN
Risk Phrases: 20/21/22 36/37/38

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
Not available.

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 175136-80-8: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: light tan
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 84 - 86 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C13H7Cl2NO
Molecular Weight: 264

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, hydrogen cyanide, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 175136-80-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-(2,4-Dichlorophenoxy)benzonitrile - Not listed by ACGIH, IARC, or NTP.

Section 12 - ECOLOGICAL INFORMATION


Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: NITRILES, SOLID, TOXIC, N.O.S.*
Hazard Class: 6.1
UN Number: 3276
Packing Group: III
IMO
Shipping Name: NITRILES, TOXIC, N.O.S.
Hazard Class: 6.1
UN Number: 3276
Packing Group: III
RID/ADR
Shipping Name: NITRILES, TOXIC, N.O.S.
Hazard Class: 6.1
UN Number: 3276
Packing group: III

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 175136-80-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 175136-80-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 175136-80-8 is not listed on the TSCA inventory.
It is for research and development use only.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Development of 3-Phenyl-<i>N</i>-(2-(3-phenylureido)ethyl)-thiophene-2-sulfonamide Compounds as Inhibitors of Antiapoptotic Bcl-2 Family Proteins
    作者:Chengwen Yang、Sha Chen、Mi Zhou、Yan Li、Yangfeng Li、Zhengxi Zhang、Zhen Liu、Qian Ba、Jingquan Li、Hui Wang、Xiaomei Yan、Dawei Ma、Renxiao Wang
    DOI:10.1002/cmdc.201400058
    日期:2014.7
    Antiapoptotic Bcl‐2 family proteins, such as Bcl‐xL, Bcl‐2, and Mcl‐1, are often overexpressed in tumor cells, which contributes to tumor cell resistance to chemotherapies and radiotherapies. Inhibitors of these proteins thus have potential applications in cancer treatment. We discovered, through structure‐based virtual screening, a lead compound with micromolar binding affinity to Mcl‐1 (inhibition
    抗凋亡的Bcl-2家族蛋白,例如Bcl-x L,Bcl-2和Mcl-1,通常在肿瘤细胞中过表达,这有助于肿瘤细胞对化学疗法和放射疗法的抗性。这些蛋白质的抑制剂因此在癌症治疗中具有潜在的应用。我们发现,通过基于结构的虚拟筛选,铅化合物与微摩尔结合亲和力Mcl-1的(抑制常数(ķ我)= 3μ中号)。它包含一个苯基四唑和一个肼基甲硫基酰胺部分,并且代表了在已知的Bcl-2抑制剂中未发现的结构支架。这项工作提出了这种先导化合物的结构优化。按照脚手架跳跃策略,我们设计并合成了三组共82种化合物。所有化合物均通过荧光偏振结合测定法进行了评估,以测量其与Bcl-x L,Bcl-2和Mcl-1的结合亲和力。一些具有3苯基噻吩-2-磺酰胺核心部分的化合物显示亚微摩尔的结合亲和力到Mcl-1的(ķ我= 0.3-0.4μ中号)或Bcl-2(ķ我≈1μ中号)。他们还显示出对肿瘤细胞的明显细胞毒性(IC 50 <
  • Compound
    申请人:Vicker Nigel
    公开号:US20090023710A1
    公开(公告)日:2009-01-22
    There is provided a compound having Formula (I) wherein each of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are independently selected from (a) H, (b) R 17 , —OC(R 17 ) 3 , —OCH(R 17 ) 2 , —OCH 2 R 17 , —C(R 17 ) 3 , —CH(R 17 ) 2 , or —CH 2 R 17 wherein R 17 is a halogen; (c) —CN; (d) optionally substituted alkyl, (e) optionally substituted heteroalkyl; (f) optionally substituted aryl; (g) optionally substituted heteroaryl; (h) optionally substituted arylalkyl; (i) optionally substituted heteroarylalkyl; (j) hydroxy; (k) alkoxy; (l) aryloxy; (m) —SO 2 -alkyl; and (n) —N(R 11 )C(O)R 13 ; wherein the optional substituents of (d) (e) (f) (h) and (i) are selected from the group consisting of: C 1-6 alkyl, halo, cyano, nitro, haloalkyl, hydroxy, alkoxy, carboxy, carboxyalkyl, carboxamide, mercapto, amino, alkylamino, dialkylamino, sulfonyl, sulfonamido, aryl and heteroaryl; each of rings A and B are selected from five or six membered carbon rings optionally containing one or more hetero atoms selected from N, S, and O and optionally having fused thereto a further ring; X is an optional group selected from O, S, S═O, S(═O) 2 , C═O, S(═O) 2 NR 8 , C═ONR 9 , NR 10 , wherein R 8 , R 9 and R 10 are independently selected from H and hydrocarbyl, wherein n and p are independently selected from 0 and 1; Y is (R 11 ) 1-3 wherein each R 11 is independently selected from NR 12 , CR 13 R 14 , S(═O) 2 and C═O, wherein R 12 , R 13 and R 14 are independently selected from Hand hydrocarbyl; Z is selected from (i) six or seven membered ring containing carbon and at least one nitrogen, which may be optionally substituted wherein the substituents may together form further ring fused thereto; and (ii) a —R 15 —NR 16 — group wherein R 15 is an optionally substituted C 1-6 alkyl chain and R 16 is selected from H and hydrocarbyl; and R 3 is selected from Formula (A).
    提供了一种具有公式(I)的化合物,其中R1、R2、R3、R4、R5、R6和R7中的每一个独立地选择自(a)H、(b)R17、—OC(R17)3、—OCH(R17)2、—OCH2R17、—C(R17)3、—CH(R17)2或—CH2R17,其中R17是卤素;(c)—CN;(d)可选取代的烷基;(e)可选取代的杂基烷基;(f)可选取代的芳基;(g)可选取代的杂芳基;(h)可选取代的芳基烷基;(i)可选取代的杂芳基烷基;(j)羟基;(k)烷氧基;(l)芳氧基;(m)—SO2-烷基;和(n)—N(R11)C(O)R13;其中(d)(e)(f)(h)和(i)的可选取代基团选自以下组中的一种:C1-6烷基,卤素,氰基,硝基,卤代烷基,羟基,烷氧基,羧基,羧基烷基,羧酰胺,硫醇基,氨基,烷基氨基,二烷基氨基,磺酰基,磺酰胺基,芳基和杂芳基;环A和环B中的每一个都选择自五元或六元碳环,可选地含有一个或多个N、S和O杂原子,并且可选地与另一个环融合;X是可选的基团,选择自O、S、S═O、S(═O)2、C═O、S(═O)2NR8、C═ONR9、NR10,其中R8、R9和R10各自独立地选择自H和烃基,其中n和p各自独立地选择自0和1;Y是(R11)1-3,其中每个R11各自独立地选择自NR12、CR13R14、S(═O)2和C═O,其中R12、R13和R14各自独立地选择自H和烃基;Z选择自(i)含有碳和至少一个氮的六元或七元环,可以选择地取代,其中取代基可以共同形成进一步融合的环;和(ii)一个—R15—NR16—基团,其中R15是可选取代的C1-6烷基链,而R16选择自H和烃基;而R3选择自公式(A)。
  • Heterocyclic compounds as inhibitors of 17beta-HSD3
    申请人:Sterix Limited
    公开号:US08119627B2
    公开(公告)日:2012-02-21
    There is provided a compound having Formula (I) wherein each of rings A and B is selected from five or six membered carbon rings optionally containing one or more hetero atoms selected from N, S, and O and optionally having fused thereto a further ring; X is an optional group selected from O, S, —S═O, —S(═O)2, —C═O, —S(═O)2NR8, —C═ONR9, and —NR10, wherein n and p are independently selected from 0 and 1; Y is (R11)1-3 wherein each R11 is independently selected from —NR12, —CR13R14, —S(═O)2 and —C═O; Z is selected from (i) six or seven membered ring containing carbon and at least one nitrogen, which may be optionally substituted wherein the substituents may together form further ring fused thereto; and (ii) a —R15—NR16— group.
    提供了一个化合物,其化学式为(I),其中环A和B分别选自含有N、S、O等一种或多种杂原子的五元或六元碳环,且可选择进一步融合的环;X是可选的基团,选自O、S、—S═O、—S(═O)2、—C═O、—S(═O)2NR8、—C═ONR9和—NR10,其中n和p独立地选自0和1;Y是(R11)1-3,其中每个R11独立地选自—NR12、—CR13R14、—S(═O)2和—C═O;Z选自(i)含有碳和至少一个氮的六元或七元环,可选择进行取代,其中取代基可共同形成进一步融合的环;以及(ii)一个—R15—NR16—基团。
  • CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS
    申请人:NOVO NORDISK A/S
    公开号:EP1268483A1
    公开(公告)日:2003-01-02
  • 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 (17BETA-HSD3) INHIBITORS
    申请人:Sterix Limited
    公开号:EP1960347B1
    公开(公告)日:2012-06-20
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐